Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia

Overview

Journal Neurol Ther

Publisher Springer

Date 2025 Jan 13

PMID 39806095

Authors

Michele H Potashman

Evan Popoff

Lauren C Powell

Melissa Wolfe Beiner

Ainsley Mackenzie

Vlad Coric

Sub Subramony

Matthis Synofzik

Jeremy Schmahmann

Gilbert LItalien

Affiliations

Soon will be listed here.

Abstract

Introduction: The Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL) is a valid, highly utilized measure for assessing ADL impacts in patients with Friedreich ataxia. We provide evidence of the psychometric validity of the FARS-ADL in two cohorts of patients with spinocerebellar ataxia (SCA).

Methods: Using data from a cohort of real-world subjects with SCA (recruited at Massachusetts General Hospital [MGH]; n = 33) and a phase 3 trial of troriluzole in adults with SCA (NCT03701399 [Study 206]; n = 217), comprising a subset of patients with the SCA3 genotype (n = 89), the psychometric measurement properties and minimal change thresholds of the FARS-ADL were examined.

Results: Ceiling effects for the FARS-ADL were absent within the MGH cohort while floor effects were observed for eight of nine items. Excellent internal consistency reliability was observed (α = 0.88; α = 0.86-0.87), and item-to-total correlations were acceptable (r = 0.55-0.89 per item). Convergent and divergent validity were supported with strong correlations demonstrated between FARS-ADL and scales measuring similar concepts (Neuro-QOL [Upper], Neuro-QOL [Lower], PROM-ADL, PROM-PHYS, and FARS-FUNC; all P < 0.001) and weaker correlations shown between measures of differing constructs. A two- to three-point threshold for meaningful changes was supported as 0.5 × SD = 2.43, SEM = 2.19. Mean changes from baseline for subjects classified as "improved," "no change," or "deteriorated" were -0.54, 0.22, and 1.47, respectively. Similar trends were observed in the Study 206 all-SCA and SCA3 cohorts.

Conclusion: Psychometric evaluation showed that the FARS-ADL performed well on analyses examining the reliability and validity of the measure and can detect meaningful changes in patients with SCA, including those with SCA3.

Trial Registration: ClinicalTrials.gov identifier, NCT03701399 (Study 206).

References

Yap K, Azmin S, Che Hamzah J, Ahmad N, van de Warrenburg B, Mohamed Ibrahim N . Pharmacological and non-pharmacological management of spinocerebellar ataxia: A systematic review. J Neurol. 2021; 269(5):2315-2337. DOI: 10.1007/s00415-021-10874-2. View

Bodranghien F, Bastian A, Casali C, Hallett M, Louis E, Manto M . Consensus Paper: Revisiting the Symptoms and Signs of Cerebellar Syndrome. Cerebellum. 2015; 15(3):369-91. PMC: 5565264. DOI: 10.1007/s12311-015-0687-3. View

Sullivan R, Yau W, OConnor E, Houlden H . Spinocerebellar ataxia: an update. J Neurol. 2018; 266(2):533-544. PMC: 6373366. DOI: 10.1007/s00415-018-9076-4. View

Lieto M, Riso V, Galatolo D, Rossi S, Barghigiani M, Cocozza S . The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families. Eur J Neurol. 2019; 27(3):498-505. DOI: 10.1111/ene.14094. View

Brooker S, Edamakanti C, Akasha S, Kuo S, Opal P . Spinocerebellar ataxia clinical trials: opportunities and challenges. Ann Clin Transl Neurol. 2021; 8(7):1543-1556. PMC: 8283160. DOI: 10.1002/acn3.51370. View

Klockgether T, Mariotti C, Paulson H . Spinocerebellar ataxia. Nat Rev Dis Primers. 2019; 5(1):24. DOI: 10.1038/s41572-019-0074-3. View

Hengel H, Pellerin D, Wilke C, Fleszar Z, Brais B, Haack T . As Frequent as Polyglutamine Spinocerebellar Ataxias: SCA27B in a Large German Autosomal Dominant Ataxia Cohort. Mov Disord. 2023; 38(8):1557-1558. DOI: 10.1002/mds.29559. View

Globas C, Tezenas du Montcel S, Baliko L, Boesch S, Depondt C, DiDonato S . Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord. 2008; 23(15):2232-8. DOI: 10.1002/mds.22288. View

Pellerin D, Danzi M, Renaud M, Houlden H, Synofzik M, Zuchner S . Spinocerebellar ataxia 27B: A novel, frequent and potentially treatable ataxia. Clin Transl Med. 2024; 14(1):e1504. PMC: 10819088. DOI: 10.1002/ctm2.1504. View

10.

Diallo A, Jacobi H, Cook A, Labrum R, Durr A, Brice A . Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol. 2018; 17(4):327-334. DOI: 10.1016/S1474-4422(18)30042-5. View

11.

Schmitz-Hubsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R . Self-rated health status in spinocerebellar ataxia--results from a European multicenter study. Mov Disord. 2010; 25(5):587-95. DOI: 10.1002/mds.22740. View

12.

Sanchez-Lopez C, Perestelo-Perez L, Escobar A, Lopez-Bastida J, Serrano-Aguilar P . Health-related quality of life in patients with spinocerebellar ataxia. Neurologia. 2015; 32(3):143-151. DOI: 10.1016/j.nrl.2015.09.002. View

13.

Ashizawa T, Oz G, Paulson H . Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol. 2018; 14(10):590-605. PMC: 6469934. DOI: 10.1038/s41582-018-0051-6. View

14.

Stephen C, Brizzi K, Bouffard M, Gomery P, Sullivan S, Mello J . The Comprehensive Management of Cerebellar Ataxia in Adults. Curr Treat Options Neurol. 2019; 21(3):9. DOI: 10.1007/s11940-019-0549-2. View

15.

Schmitz-Hubsch T, Tezenas Du Montcel S, Baliko L, Berciano J, Boesch S, Depondt C . Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006; 66(11):1717-20. DOI: 10.1212/01.wnl.0000219042.60538.92. View

16.

Subramony S, May W, Lynch D, Gomez C, Fischbeck K, Hallett M . Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology. 2005; 64(7):1261-2. DOI: 10.1212/01.WNL.0000156802.15466.79. View

17.

Perez-Lloret S, van de Warrenburg B, Rossi M, Rodriguez-Blazquez C, Zesiewicz T, Saute J . Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. Mov Disord. 2020; 36(2):283-297. DOI: 10.1002/mds.28313. View

18.

Rummey C, Corben L, Delatycki M, Subramony S, Bushara K, Gomez C . Psychometric properties of the Friedreich Ataxia Rating Scale. Neurol Genet. 2020; 5(6):371. PMC: 6927357. DOI: 10.1212/NXG.0000000000000371. View

19.

Lynch D, Farmer J, Tsou A, Perlman S, Subramony S, Gomez C . Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology. 2006; 66(11):1711-6. DOI: 10.1212/01.wnl.0000218155.46739.90. View

20.

Friedman L, Farmer J, Perlman S, Wilmot G, Gomez C, Bushara K . Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010; 25(4):426-32. PMC: 2954653. DOI: 10.1002/mds.22912. View